1
|
Hopkin SJ, Nathan P, Pezhman L, Begum J, Manning JE, Quinn LM, Rainger GE, McGettrick HM, Iqbal AJ, Chimen M. Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. NPJ AGING 2024; 10:33. [PMID: 39025913 PMCID: PMC11258258 DOI: 10.1038/s41514-024-00160-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 06/24/2024] [Indexed: 07/20/2024]
Abstract
Inflammageing leads to uncontrolled leukocyte trafficking in response to inflammatory insults. Here, we used a zymosan-induced peritonitis mouse model on inflammation to investigate the role of the PEPITEM pathway on leukocyte migration in ageing. We then analysed whether PEPITEM could modulate leukocyte migration in older adults. We observed a loss of functionality in the PEPITEM pathway, which normally controls leukocyte trafficking in response to inflammation, in older adults and aged mice and show that this can be rescued by supplementation with PEPITEM. Thus, leading to the exciting possibility that PEPITEM supplementation may represent a potential pre-habilitation geroprotective agent to rejuvenate immune functions.
Collapse
Affiliation(s)
- Sophie J Hopkin
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Poppy Nathan
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Laleh Pezhman
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Jenefa Begum
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Julia E Manning
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK
| | - Lauren M Quinn
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - G Ed Rainger
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Helen M McGettrick
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK.
| | - Asif J Iqbal
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
| | - Myriam Chimen
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK.
| |
Collapse
|
2
|
Lewis JW, Frost K, Neag G, Wahid M, Finlay M, Northall EH, Abudu O, Kemble S, Davis ET, Powell E, Palmer C, Lu J, Rainger GE, Iqbal AJ, Chimen M, Mahmood A, Jones SW, Edwards JR, Naylor AJ, McGettrick HM. Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss. Cell Rep Med 2024; 5:101574. [PMID: 38776873 PMCID: PMC11148860 DOI: 10.1016/j.xcrm.2024.101574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/29/2024] [Accepted: 04/23/2024] [Indexed: 05/25/2024]
Abstract
The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM) with anabolic osteogenic activity, regulating bone remodeling in health and disease. PEPITEM acts directly on osteoblasts through NCAM-1 signaling to promote their maturation and formation of new bone, leading to enhanced trabecular bone growth and strength. Simultaneously, PEPITEM stimulates an inhibitory paracrine loop: promoting osteoblast release of the decoy receptor osteoprotegerin, which sequesters RANKL, thereby limiting osteoclast activity and bone resorption. In disease models, PEPITEM therapy halts osteoporosis-induced bone loss and arthritis-induced bone damage in mice and stimulates new bone formation in osteoblasts derived from patient samples. Thus, PEPITEM offers an alternative therapeutic option in the management of diseases with excessive bone loss, promoting an endogenous anabolic pathway to induce bone remodeling and redress the imbalance in bone turnover.
Collapse
Affiliation(s)
- Jonathan W Lewis
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Kathryn Frost
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Georgiana Neag
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Mussarat Wahid
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Melissa Finlay
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Ellie H Northall
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Oladimeji Abudu
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Samuel Kemble
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Edward T Davis
- Royal Orthopaedic Hospital, Bristol Road, Birmingham B31 2AP, UK
| | - Emily Powell
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Charlotte Palmer
- Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK
| | - Jinsen Lu
- Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK
| | - G Ed Rainger
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
| | - Asif J Iqbal
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
| | - Myriam Chimen
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Ansar Mahmood
- Department of Trauma and Orthopaedics, University Hospitals NHS Foundation Trust, Edgbaston, Birmingham B15 2GW, UK
| | - Simon W Jones
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - James R Edwards
- Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK
| | - Amy J Naylor
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK
| | - Helen M McGettrick
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK.
| |
Collapse
|
3
|
Alassiri M, Al Sufiani F, Aljohi M, Alanazi A, Alhazmi AS, Alrfaei BM, Alnakhli H, Alshawakir YA, Alharby SM, Almubarak AY, Alasseiri M, Alorf N, Abdullah ML. PEPITEM Treatment Ameliorates EAE in Mice by Reducing CNS Inflammation, Leukocyte Infiltration, Demyelination, and Proinflammatory Cytokine Production. Int J Mol Sci 2023; 24:17243. [PMID: 38139072 PMCID: PMC10743148 DOI: 10.3390/ijms242417243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 09/30/2023] [Accepted: 10/09/2023] [Indexed: 12/24/2023] Open
Abstract
To investigate the effect of the therapeutic treatment of the immunopeptide, peptide inhibitor of trans-endothelial migration (PEPITEM) on the severity of disease in a mouse model of experimental autoimmune encephalomyelitis (EAE) as a model for human multiple sclerosis (MS), a series of experiments were conducted. Using C57BL/6 female mice, we dosed the PEPITEM in the EAE model via IP after observing the first sign of inflammation. The disease was induced using MOG35-55 and complete Freund's adjuvants augmented with pertussis toxin. The EAE score was recorded daily until the end of the experiment (21 days). The histological and immunohistochemistry analysis was conducted on the spinal cord sections. A Western blot analysis was performed to measure the protein concentration of MBP, MAP-2, and N-Cadherin, and ELISA kits were used to measure IL-17 and FOXP3 in the serum and spinal cord lysate. The therapeutic treatment with PEPITEM reduced the CNS infiltration of T cells, and decreased levels of the protein concertations of MBP, MAP-2, and N-Cadherin were observed, in addition to reduced concertations of IL-17 and FOXP3. Using PEPITEM alleviated the severity of the symptoms in the EAE model. Our study revealed the potential of PEPITEM to control inflammation in MS patients and to reduce the harmful effects of synthetic drugs.
Collapse
Affiliation(s)
- Mohammed Alassiri
- Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Riyadh 11481, Saudi Arabia; (M.A.); (A.S.A.)
- Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City (KAMC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia; (F.A.S.); (H.A.)
| | - Fahd Al Sufiani
- Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City (KAMC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia; (F.A.S.); (H.A.)
| | - Mohammed Aljohi
- Healthy Aging Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia; (M.A.); (N.A.)
| | - Asma Alanazi
- Department of Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), King Abdulaziz Medical City (KAMC), Riyadh 11481, Saudi Arabia; (A.A.); (B.M.A.)
| | - Aiman Saud Alhazmi
- Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Riyadh 11481, Saudi Arabia; (M.A.); (A.S.A.)
- Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City (KAMC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia; (F.A.S.); (H.A.)
| | - Bahauddeen M. Alrfaei
- Department of Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), King Abdulaziz Medical City (KAMC), Riyadh 11481, Saudi Arabia; (A.A.); (B.M.A.)
- Department of Cellular Therapy and Cancer Research, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia
| | - Hasan Alnakhli
- Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City (KAMC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia; (F.A.S.); (H.A.)
| | - Yasser A. Alshawakir
- Department of Experimental Surgery and Animal Laboratory, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia; (Y.A.A.); (S.M.A.); (A.Y.A.)
| | - Saleh M. Alharby
- Department of Experimental Surgery and Animal Laboratory, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia; (Y.A.A.); (S.M.A.); (A.Y.A.)
| | - Abdullah Y. Almubarak
- Department of Experimental Surgery and Animal Laboratory, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia; (Y.A.A.); (S.M.A.); (A.Y.A.)
| | - Mohammed Alasseiri
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 47512, Saudi Arabia;
| | - Nora Alorf
- Healthy Aging Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia; (M.A.); (N.A.)
| | - Mashan L. Abdullah
- Department of Experimental Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh 11481, Saudi Arabia
| |
Collapse
|
4
|
Gattringer J, Gruber CW, Hellinger R. Peptide modulators of cell migration: Overview, applications and future development. Drug Discov Today 2023; 28:103554. [PMID: 36921670 PMCID: PMC7615922 DOI: 10.1016/j.drudis.2023.103554] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 03/07/2023] [Accepted: 03/08/2023] [Indexed: 03/14/2023]
Abstract
Cell migration is a key physiological process in the development and homeostasis of multicellular organisms; errors in this complex system can trigger the development of cancer or inflammatory disorders. Therefore, modulating cell migration provides opportunities for drug discovery. Peptides are gaining importance on the global therapeutics market, given their unique properties compared with established small-molecule drugs or biologics. In this review, we identified over 470 peptides modulating cell migration and analyzed their characteristics. Over 95% of these peptides are in the discovery or preclinical stage, because the transition of peptide hits into drug leads often results in a bottleneck in the development process. We summarize chemical strategies in (pre-)clinical development to enhance drug-like properties of bioactive peptides.
Collapse
Affiliation(s)
- Jasmin Gattringer
- Medical University of Vienna, Center for Physiology and Pharmacology, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - Christian W Gruber
- Medical University of Vienna, Center for Physiology and Pharmacology, Schwarzspanierstrasse 17, A-1090 Vienna, Austria
| | - Roland Hellinger
- Medical University of Vienna, Center for Physiology and Pharmacology, Schwarzspanierstrasse 17, A-1090 Vienna, Austria.
| |
Collapse
|
5
|
Pezhman L, Hopkin SJ, Begum J, Heising S, Nasteska D, Wahid M, Ed Rainger G, Hodson DJ, Iqbal AJ, Chimen M, McGettrick HM. PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clin Exp Immunol 2023; 212:1-10. [PMID: 36891817 PMCID: PMC10081110 DOI: 10.1093/cei/uxad022] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 01/10/2023] [Accepted: 02/13/2023] [Indexed: 03/10/2023] Open
Abstract
Dysregulation of leukocyte trafficking, lipid metabolism, and other metabolic processes are the hallmarks that underpin and drive pathology in obesity. Current clinical management targets alternations in lifestyle choices (e.g. exercise, weight loss) to limit the impact of the disease. Crucially, re-gaining control over the pathogenic cellular and molecular processes may offer an alternative, complementary strategy for obese patients. Here we investigate the impact of the immunopeptide, PEPITEM, on pancreas homeostasis and leukocyte trafficking in mice on high-fed obesogenic diet (HFD). Both prophylactic and therapeutic treatment with PEPITEM alleviated the effects of HFD on the pancreas, reducing pancreatic beta cell size. Moreover, PEPITEM treatment also limited T-cell trafficking (CD4+ T-cells and KLRG1+ CD3+ T-cells) to obese visceral, but not subcutaneous, adipose tissue. Similarly, PEPITEM treatment reduced macrophage numbers within the peritoneal cavity of mice on HFD diet at both 6 and 12 weeks. By contrast, PEPITEM therapy elevated numbers of T and B cells were observed in the secondary lymphoid tissues (e.g. spleen and inguinal lymph node) when compared to the untreated HFD controls. Collectively our data highlights the potential for PEPITEM as a novel therapy to combat the systemic low-grade inflammation experienced in obesity and minimize the impact of obesity on pancreatic homeostasis. Thus, offering an alternative strategy to reduce the risk of developing obesity-related co-morbidities, such as type 2 diabetes mellitus, in individuals at high risk and struggling to control their weight through lifestyle modifications.
Collapse
Affiliation(s)
- Laleh Pezhman
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
| | - Sophie J Hopkin
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Jenefa Begum
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Silke Heising
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
| | - Daniela Nasteska
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
| | - Mussarat Wahid
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
| | - G Ed Rainger
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - David J Hodson
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
| | - Asif J Iqbal
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Myriam Chimen
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
| | - Helen M McGettrick
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
| |
Collapse
|